title: Effects of an antimalarial quinazoline derivative on human erythrocytes and on cell membrane molecular models.
abstract: Plasmodium, the parasite which causes malaria in humans multiplies in the liver and then infects circulating erythrocytes. Thus, the role of the erythrocyte cell membrane in antimalarial drug activity and resistance has key importance. The effects of the antiplasmodial N(6)-(4-methoxybenzyl)quinazoline-2,4,6-triamine (M4), and its inclusion complex (M4/HPβCD) with 2-hydroxypropyl-β-cyclodextrin (HPβCD) on human erythrocytes and on cell membrane molecular models are herein reported. This work evidences that M4/HPβCD interacts with red cells as follows: a) in scanning electron microscopy (SEM) studies on human erythrocytes induced shape changes at a 10μM concentration; b) in isolated unsealed human erythrocyte membranes (IUM) a concentration as low as 1μM induced sharp DPH fluorescence anisotropy decrease whereas increasing concentrations produced a monotonically decrease of DPH fluorescence lifetime at 37°C; c) X-ray diffraction studies showed that 200μM induced a complete structural perturbation of dimyristoylphosphatidylcholine (DMPC) bilayers whereas no significant effects were detected in dimyristoylphosphatidylethanolamine (DMPE) bilayers, classes of lipids present in the outer and inner monolayers of the human erythrocyte membrane, respectively; d) fluorescence spectroscopy data showed that increasing concentrations of the complex interacted with the deep hydrophobic core of DMPC large unilamellar vesicles (LUV) at 18°C. All these experiments are consistent with the insertion of M4/HPβCD in the outer monolayer of the human erythrocyte membrane; thus, it can be considered a promising and novel antimalarial agent.
authors.affiliation: Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico.
authors.forename: Yareli
authors.initials: Y
authors.lastname: Rojas-Aguirre
authors.forename: Francisco
authors.initials: F
authors.lastname: Hernández-Luis
authors.forename: César
authors.initials: C
authors.lastname: Mendoza-Martínez
authors.forename: Carlos Patricio
authors.initials: CP
authors.lastname: Sotomayor
authors.forename: Luis Felipe
authors.initials: LF
authors.lastname: Aguilar
authors.forename: Fernando
authors.initials: F
authors.lastname: Villena
authors.forename: Ivan
authors.initials: I
authors.lastname: Castillo
authors.forename: David J
authors.initials: DJ
authors.lastname: Hernández
authors.forename: Mario
authors.initials: M
authors.lastname: Suwalsky
mesh_terms: D000962:Antimalarials / Q000737:chemistry* / Q000494:pharmacology; D004134:Dimyristoylphosphatidylcholine / Q000737:chemistry / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004910:Erythrocyte Membrane / Q000737:chemistry* / Q000378:metabolism / Q000648:ultrastructure; D006801:Humans; D008051:Lipid Bilayers / Q000737:chemistry / Q000378:metabolism; D008958:Models, Molecular; D010714:Phosphatidylethanolamines / Q000737:chemistry / Q000378:metabolism; D011799:Quinazolines / Q000737:chemistry* / Q000494:pharmacology
chemical_list: D000962:Antimalarials; D008051:Lipid Bilayers; D010714:Phosphatidylethanolamines; D011799:Quinazolines; D004134:Dimyristoylphosphatidylcholine; C018525:1,2-dimyristoylphosphatidylethanolamine